HomeCompanyTechnologyPipelineInvestors & MediaContact

In the clinic

Hepatocellular carcinoma (HCC), the most frequent subtype of liver cancer, is the third leading cause of cancer death in the world.  About 50 to 80% of HCC cases are caused by Hepatitis B virus (HBV) infection, a major health problem that afflicts 270 million people worldwide. 

Our lead product, LioCyx-M, an autologous T-cell product transfected with mRNA encoding HBV antigen-specific TCR, has been used clinically for the treatment of HBV-related liver cancer and recurrent HBV-related liver cancer post liver transplant.

Contact us at clinicaltrials@liontcr.com for more information.

Study ID

Indication

Pre-Clinical

Phase 1

Phase 2

LTCR-H3-5
Advanced Primary HBV-HCC (monotherapy and combinational-therapy)
Upcoming
LTCR-H3-3
Biomarker study for Advanced Primary HBV-HCC
Upcoming
LTCR-H1-1
Prevention of HCC Recurrence Post-Liver Transplantation
LTCR-H2-1
Treatment of HCC Recurrence Post-Liver Transplantation
LTCR-H3-1
Treatment of Advanced Primary HBV-HCC
LTCR-C2-1
Treatment of Chronic HBV Infection
LTCR-N1-1
Treatment of EBV-related Nasopharyngeal Carcinoma
LTCR-O1-1
Treatment of Post-Transplant Lympho-proliferative Disorders

Project
Details

LTCR-H3-5

Advanced Primary HBV-HCC (monotherapy and combinational therapy)

Status: Upcoming

Study Type: Multi-center, multi-arm,open-label Phase 1b/2 study

Objective: To determine safety and efficacy of LioCyx-M as a monotherapy and as a combinational therapy with existing standard of care drug sorafenib or lenvatinib in primary HCC patients

LTCR-H3-3

Biomarker study for Advanced Primary HBV-HCC

Status: Upcoming

Study Type: Single center, single arm, open-label Phase 1 study

Objective: To determine the safety of LioCyx-M and to analyze the changes in tumor microenvironment caused by LioCyx-M in patients with HBV-related HCC who are not amenable to/failed conventional treatment

LTCR-H1-1

Prevention of HCC Recurrence Post-Liver Transplantation

Status: Upcoming

Study Type: Single center, single arm, open-label Phase 1 study

Objective: To assess the safety and efficacy of LioCyx-M to prevent HCC recurrence post liver transplantation for patients with HBV-related HCC after liver transplantation

LTCR-H2-1

Treatment of HCC Recurrence Post-Liver Transplantation

Status: Completed (SITC 2020)

Study Type: Single center, single arm, open-labelPhase 1 study

Objective: To assess the safety and efficacy of LioCyx-M for patients with recurrent HBV-related HCC post liver transplantation

LTCR-H3-1

Treatment of Advanced Primary HBV-HCC

Status: Completed (SITC 2020, EASL DILC 2021)

Study Type: Single center, single arm, open-label Phase 1 study

Objective: To assess the safety and efficacy of LioCyx-M for patients with advanced primary HBV-HCC

Hospital Partners